Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss

    November 2024 in “ JAMA Dermatology
    Yagiz Matthew Akiska, Paradi Mirmirani, Ingrid Roseborough, Erin F. Mathes, Tina Bhutani, Andrew P. Ambrosy, Crystal Aguh, Wilma F. Bergfeld, Valerie Callender, Leslie Castelo‐Soccio, George Cotsarelis, Brittany G. Craiglow, Nisha S. Desai, Isabella Doche, Bruna Duque‐Estrada, Dirk M. Elston, Carolyn Goh, Lynne J. Goldberg, Ramón Grimalt, Ali Jabbari, Victoria Jolliffe, Brett King, Charlotte LaSenna, Yolanda M. Lenzy, Jenna Lester, Nino Lortkipanidze, Kristen I. Lo Sicco, Amy McMichael, Nekma Meah, Natasha Atanaskova Mesinkovska, Mariya Miteva, Arash Mostaghimi, Yuliya Ovcharenko, Melissa Piliang, Bianca Maria Piraccini, Adriana Rakowska, Kimberly Salkey, Adriana N. Schmidt, Jerry Shapiro, Cathryn Sibbald, Rodney Sinclair, Poonkiat Suchonwanit, Susan S. Taylor, Antonellá Tosti, Sergio Vañó‐Galván, Dmitri Wall, Jennifer M. Fu
    Image of study
    An international expert consensus statement was developed to guide the off-label use of low-dose oral minoxidil (LDOM) for hair loss, involving 43 dermatologists from 12 countries. Through a modified Delphi process, consensus was reached on 76 items, including diagnoses, dosing for adults and adolescents, contraindications, and monitoring. However, consensus was not achieved for pediatric use and titration protocols. The statement aims to assist clinical practice until more data are available, highlighting the need for further research on pediatric use, comparative efficacy with topical minoxidil, long-term safety, and other off-label minoxidil forms.
    Discuss this study in the Community →

    Research cited in this study

    22 / 22 results

    Related Community Posts Join

    6 / 1000+ results

    Related Research

    9 / 9 results